The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
11'-(2-chlorophenyl)-8'-methyl-4',5',10',11'-tetrahydrospiro[cyclopentane-1,3'-dibenzo[b,e][1,4]diazepin]-1'(2'H)-one ID: ALA562834
Max Phase: Preclinical
Molecular Formula: C24H25ClN2O
Molecular Weight: 392.93
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: Cc1ccc2c(c1)NC(c1ccccc1Cl)C1=C(CC3(CCCC3)CC1=O)N2
Standard InChI: InChI=1S/C24H25ClN2O/c1-15-8-9-18-19(12-15)27-23(16-6-2-3-7-17(16)25)22-20(26-18)13-24(14-21(22)28)10-4-5-11-24/h2-3,6-9,12,23,26-27H,4-5,10-11,13-14H2,1H3
Standard InChI Key: QWCJEASGZREXEI-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 32 0 0 0 0 0 0 0 0999 V2000
4.7033 -6.1094 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4504 -6.4591 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0140 -5.8566 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.6151 -5.1345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8051 -5.2907 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5562 -8.4749 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7245 -9.2825 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1092 -9.8321 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3256 -9.5740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1573 -8.7664 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7726 -8.2168 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6043 -7.4091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6394 -5.5557 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.8036 -7.2103 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.2746 -6.0822 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2589 -6.9071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9655 -7.3331 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6876 -6.9342 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9968 -5.6834 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4598 -6.4604 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8318 -5.7240 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3801 -5.0337 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5564 -5.0797 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1844 -5.8161 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6361 -6.5064 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6394 -5.8621 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9498 -8.1579 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.3737 -8.5083 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
6 7 2 0
20 14 1 0
16 12 1 0
14 12 1 0
15 16 2 0
2 3 1 0
7 8 1 0
3 4 1 0
8 9 2 0
4 5 1 0
15 19 1 0
16 17 1 0
17 18 1 0
18 1 1 0
1 19 1 0
9 10 1 0
5 1 1 0
20 21 2 0
10 11 2 0
21 22 1 0
11 6 1 0
22 23 2 0
1 2 1 0
23 24 1 0
11 12 1 0
24 25 2 0
25 20 1 0
24 26 1 0
21 13 1 0
17 27 2 0
13 15 1 0
10 28 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 392.93Molecular Weight (Monoisotopic): 392.1655AlogP: 6.40#Rotatable Bonds: 1Polar Surface Area: 41.13Molecular Species: NEUTRALHBA: 3HBD: 2#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: 11.80CX Basic pKa: 2.58CX LogP: 5.11CX LogD: 5.11Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.59Np Likeness Score: -0.67
References 1. Fu J, Shuttleworth SJ, Connors RV, Chai A, Coward P.. (2009) Discovery and optimization of a novel Neuromedin B receptor antagonist., 19 (15): [PMID:19553112 ] [10.1016/j.bmcl.2009.05.124 ]